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Special Article
Iron supplementation in preterm and low birth weight infants:
a systematic review of intervention studies
Elaine K. McCarthy, Eugene M. Dempsey, and Mairead E. Kiely
Context: Enteral iron supplementation in preterm infants is recommended to supply
sufficient iron for growth and development without increasing the risk of iron over-
load. However, the current recommendations date from 2010 and are based on lim-
ited evidence. Objective: This systematic review aimed to investigate the effects of
enteral iron supplementation on iron status, growth, neurological development, and
adverse clinical outcomes in preterm (<37 weeks’ gestation) and low-birth-weight
(LBW, <2500 g) infants. Data sources: The PubMed/Medline and Cochrane Library
databases were searched to 31 October 2018. Data extraction: Of the 684 records
identified, 27 articles, describing 18 randomized controlled trials (RCTs) plus 4 non-
randomized interventions, were included. Using the Cochrane Collaboration’s criteria,
study quality was found to be poor to fair overall. Results: Most articles (23/27)
reported iron status indices; supplementation for8weeks resulted in increased hemo-
globin and ferritin concentrations and a reduction in iron deficiency and anemia. No
article reported on iron overload. Growth-related parameters reported in 12 articles
were not affected by supplementation. Among the 7 articles on neurological develop-
ment, a positive effect on behavior at 3.5 and 7 years was observed in one Swedish
RCT. No association was found between supplementation and adverse clinical out-
comes in the 9 articles reporting on studies in which such data was collected.
Conclusions: Long-term iron supplementation appears to result in improved iron sta-
tus and a reduction in iron deficiency and anemia in preterm and LBW infants.
However, high-quality evidence regarding the long-term effects of supplementation on
functional health outcomes is lacking. Iron overload has largely been ignored. Well-
designed, long-term, dose-response RCTs are required to ascertain the optimal dose
and delivery method for the provision of dietary iron in preterm infants, with consider-
ation of short- and long-term health effects. Systematic Review Registration:
PROSPERO registration no. CRD42018085214.
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INTRODUCTION
Iron deficiency in early life adversely affects the growth
and functioning of multiple organ systems.1 The effects
of iron deficiency on the developing brain are perma-
nent and life-altering.2,3 Preterm infants are deprived of
the significant iron accretion that occurs in the third tri-
mester of pregnancy and have reduced iron stores at
birth compared with term infants.4,5 Pregnancy compli-
cations, including gestational diabetes mellitus and fetal
growth restriction, as well as maternal lifestyle factors
such as smoking and obesity, also compromise infant
iron stores.6,7 Apart from the considerable impact of
preterm birth itself, infants delivered preterm are at
high risk of iron deficiency owing to the increased post-
natal iron required to facilitate rapid growth and an ear-
lier onset of erythropoiesis, which occurs 1–3months
earlier than in term infants.8,9
Iron supplementation is recommended for preterm
infants, although extreme caution is warranted, as the
potential risk of iron overload is high. High iron doses
from supplementation or blood transfusions can result
in excess iron, leading to free circulating Fe2þ ions,
which contribute to the production of reactive oxygen
species that can affect sensitive organ systems, such as
the heart, liver, pancreas, and developing brain.10
Therefore, a balance in the provision of adequate iron is
required to ensure optimal growth and development
without contributing to iron overload.
To achieve this balance, international intake rec-
ommendations for enteral iron in preterm infants are
2–3mg/kg/d from the age of 2–6weeks until at least 6–
12months.11,12 Higher iron doses (>5mg/kg/d) are
only recommended for infants who are receiving eryth-
ropoietin treatment or for those that have experienced
significant, uncompensated blood losses.11 These rec-
ommendations, made in 2010, were based on a limited
evidence basis, with significant heterogeneity in trial de-
sign and iron treatment doses among studies that pri-
marily focused on the effects of supplementation in
relation to hematological parameters. Systematic
reviews in 2012 highlighted the lack of evidence regard-
ing the effect of iron supplementation on functional
health outcomes, particularly long-term growth and
neurological development.13,14
Following the 2010 recommendations and 2012
reviews, the availability of relevant intervention studies
has increased. Therefore, the primary objective of the
present work was to perform an updated systematic re-
view to examine the effect of enteral iron supplementa-
tion on health outcomes in preterm and low-birth-weight
(LBW,<2500 g) infants. The main health outcomes of in-
terest were iron status, growth, and neurological develop-
ment. A secondary objective was to investigate
associations between supplementation and adverse clini-
cal outcomes.
METHODS
The protocol for this systematic review was developed
in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines and was registered prospectively with
PROSPERO (CRD42018085214).
Search strategy
The PubMed/Medline and Cochrane Library databases
were searched up to October 31, 2018. A structured
search strategy was devised, incorporating the Medical
Subject Headings (MeSH) search terms “Infant, Low
Birth Weight,” “Infant, Extremely Low Birth Weight,”
“Infant, Very Low Birth Weight,” “Infant, Premature,”
“Infant, Extremely Premature,” “Premature Birth” or
text words “preterm,” “premature” AND MeSH terms
“Iron,” “Iron, Dietary,” “ferrous” or text words “iron
intake,” “iron supplementation,” “iron supplements,”
“ferrous sulphate/fumarate/sulfate,” “dietary iron
intake.” Eligible studies were limited to English lan-
guage articles only. The bibliographies of identified
studies and key review (narrative and systematic/meta-
analyses) articles were searched manually and incorpo-
rated into the current review in accordance with the
eligibility criteria. Clinical trial registries were also
searched for ongoing or recently completed trials.
Eligibility criteria
Studies in infants born premature (<37 wk’ gestation) or
with a birth weight <2500 g investigating the effect of en-
teral iron supplementation on health outcomes, includ-
ing iron status, growth, neurological development, and
adverse clinical outcomes, were eligible for inclusion
(Table 1). Studies in which enteral iron supplementation
was provided with concurrent erythropoietin treatment
were not eligible. Narrative reviews, case reports, com-
ments, and editorials were also excluded.
Data collection
Following removal of duplicates, the titles and abstracts
of all records retrieved from the search were screened
independently by two researchers (E.K.M. and M.E.K.)
to assess compliance with the eligibility criteria.
Following exclusion of unsuitable records, the full texts
of the remaining records were evaluated by all authors
and the final list of included papers was agreed upon
following discussion.
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Information on study design/methodology, partici-
pant characteristics (eg, gestational age [GA], birth
weight [BW], feeding method), interventions (dose, du-
ration, timing initiation, comparators), outcome assess-
ments (type, timing), and main findings were extracted
from each study using an internally piloted,
standardized data collection form. The duration of sup-
plementation was stratified into short-term (<8wk) and
long-term (8wk). To ensure uniformity, the iron supple-
mentation dose was standardized to mg/kg/d, using the
published mean birth weight as the body weight for this
calculation. For trials of infant formula, an estimate of the
daily intake of formula of 160mL/kg/d was applied.13
The risk of bias in study design was assessed inde-
pendently by the reviewers using the criteria set out by
the Cochrane Handbook for Systematic Reviews of
Interventions.15 These criteria were used to assess both
randomized controlled trials (RCTs) and
nonrandomized trials, and further assessment of the
risk of selection bias was performed for the
nonrandomized trials.
RESULTS
Study selection
Following the database searches, 684 records were iden-
tified and 4 duplicates were removed (Figure 1). Of the
680 records screened, 559 were excluded, mainly owing
to no reported outcome of interest or a focus on mater-
nal supplementation. Following full-text review of the
remaining records, 27 papers were eligible for inclusion
in the systematic review.
16–42
Study characteristics
The 27 included articles, characterized in Table 2,16–42
were published between 1974 and 2018 (including 7
since 2012), and most studies were conducted in
Europe and North America. In total, there were 18
RCTs, as 5 publications16,17,22–24 were derived from a
single trial conducted in Sweden.24 There were 4
nonrandomized interventions.27,29,37,42 Ten RCTs were
placebo-controlled trials involving iron supplementa-
tion vs no supplementation/human milk as
placebo19,21,24,25,30,31,35,36,38,41; 4 trials compared 2 or
more iron doses20,32,34,39; and 4 compared early (age
2wk) to late (4–8wk) initiation of
supplementation.18,28,33,40 The study by Steinmacher
et al26 is a follow-on to the trial described by Franz et
al.33 The intervention dose provided in most studies
was 2–4mg/kg/d, although doses of 6–24.2mg/kg/d
were also reported20,27,29,36,38,42 and the duration of sup-
plementation ranged from 1week to 1 year.
Outcomes from the 27 articles analyzed were de-
scribed individually because, although there were 22 in-
dividual trials, each paper assessed health outcomes
independently. This is a challenging and vulnerable
population to study. Although the overall study quality
was poor to fair, some of the recent studies were of high
quality (Table 316–42). The main source of bias in the
RCTs was a lack of allocation concealment during the
intervention (12/18 RCTs), although most did employ
an appropriate method of randomization (16/18).
Incomplete outcome data was another limitation of
many of the papers, with significant, but understand-
able, attrition of participants in studies involving long-
term follow-up. Given the large degree of heterogeneity
in study design, a quantitative comparison or meta-
analysis was inappropriate and not feasible. Particular
limitations that precluded such an analysis were the var-
iability in participant characteristics with respect to GA
and BW; differences in intervention doses, timing, and
duration of supplementation; and variability in both
outcomes and timing and methods of outcome
assessment.
Table 1 PICOS criteria for inclusion of studies
Criterion Description
Participants Infants born premature (<37 wk’ gestation) or
with a birth weight <2500 g
Intervention Iron supplementation through the enteral
route, ie, medicinal iron, infant formula, hu-
man milk fortifier
Comparison Different regimens of enteral iron supplemen-
tation, with respect to dose, duration, and
timing of initiation of supplementation
Outcomes 1. Iron status during and/or post the interven-
tion period:
a) Indices reflecting storage iron (ferritin),
transport iron (iron, transferrin, TIBC, trans-
ferrin saturation, soluble transferrin recep-
tors), and functional iron (MCV, hematocrit,
hemoglobin)
b) Prevalence of iron deficiency, iron defi-
ciency anemia, and iron overload (as de-
fined by study investigators)
2. Growth-related parameters during and/or
post the intervention period, including
weight, length, and head circumference
3. Measures of neurological development dur-
ing and/or post the intervention period,
assessed through standardized neurodeve-
lopmental assessments performed at prede-
fined time points
4. Incidence of adverse short-term clinical out-
comes (including NEC, ROP, CLD, PVL, oxida-
tive stress, and sepsis) as defined by study
investigators during and/or post the inter-
vention period
Study design Any intervention study, including RCTs and
nonrandomized trials
Abbreviations: CLD, chronic lung disease; MCV, mean corpus-
cular volume; NEC, necrotizing enterocolitis; PVL, periventricu-
lar leukomalacia; RCT, randomized controlled trial; ROP,
retinopathy of prematurity; TIBC, total iron-binding capacity.
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Effects of enteral iron supplementation
Iron status indices. The effect of supplementation on
iron status indices was assessed in 23 papers.17–21,24,25,27–42
In 8 trials, duration of supplementation was <8weeks,
and in 11 trials duration of supplementation was
8 weeks, while another 4 trials investigated the timing
of supplementation initiation. While 2 studies,27,35 in-
cluding a small nonrandomized trial of high-dose iron
(9.4mg/kg/d) in very-low-birth-weight (VLBW,
<1500 g) infants,27 observed a small effect of short-term
supplementation on iron indices, the other studies on
short-term supplementation reported no
effect.20,21,25,29,31,39 Treatment with medicinal iron, for-
mula, or human milk fortifier at 2–4mg/kg/d was found
to have no effect on ferritin, hematocrit, or hemoglobin
concentrations in VLBW infants.21,25,31,39 Additionally,
high-dose (average 7–10mg/kg/d) supplementation in
infants born at less than 32 weeks’ gestation had no ef-
fect on ferritin, iron, transferrin saturation, transferrin
receptors, or total iron-binding capacity (TIBC).20,29
Of the 11 studies in which duration of supplemen-
tation was 8weeks, 8 reported an effect on iron sta-
tus.17,19,24,30,36,37,41,42 In marginally LBW infants, a dose
of 2mg/kg/d increased circulating iron, ferritin, trans-
ferrin saturation, transferrin receptors, mean corpuscu-
lar volume (MCV), and hemoglobin at 6months
compared to the placebo group.24 Ferritin concentra-
tions remained significantly higher at 12months, but
not at 3.5 years, in the marginally LBW infants com-
pared with the placebo group.17 Supplementation with
high-dose (7.1 and 24.2mg/kg/d) medicinal iron
resulted in higher serum ferritin and iron concen-
trations.36,42 Long-term formula interventions also
reported beneficial effects on ferritin, MCV, and
hemoglobin concentrations.19,37 Three studies observed
no effect with long-term supplementation,32,34,38 in-
cluding 2 dose-comparison formula interventions,
where consumption of a higher-iron formula had no ef-
fect on ferritin, transferrin, hematocrit, or hemoglobin
concentrations compared with a lower-iron
formula.32,34
Figure 1 Flow diagram of the literature selection process.
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Four studies examined the effect of early vs late ini-
tiation of supplementation on iron status.18,28,33,40
Short-term interventions by Joy et al18 and Arnon et al28
reported higher ferritin, iron, transferrin receptors, and
hemoglobin in infants initiated at 2weeks vs 4–6weeks
of age. In the only long-term trial, no differences in fer-
ritin or hemoglobin were observed between infants that
received 2–3mg/kg/d from the age of 3weeks and those
that received the same dose from 8weeks.40
Prevalence of iron deficiency, iron deficiency anemia, and
iron overload. Nine articles reported the effect of iron
supplementation on the prevalence of iron deficiency or
iron deficiency anemia.17,19,24,32–35,37,41 It is worth not-
ing that no article reported on iron overload. In the
only short-term intervention, treatment with a high-
iron formula (2.4mg/kg/d, delivering 15mg/L)
resulted in a lower prevalence of low serum ferritin
(<19 ng/mL) (32% in the high-iron vs 79% in the low-
iron group) and anemia (hemoglobin <9 g/dL) (26% vs
70%) than treatment with a low-iron formula (0.5mg/
kg/d, delivering 3mg/L).35 The prevalence of low ferri-
tin among infants receiving fortified human milk (deliv-
ering 1.7mg/L) was 23%, and 77% were anemic.
In 2 long-term RCTs looking at formula milk, a re-
duced incidence of iron deficiency was observed in the
formula-fed groups compared to the human milk–fed
groups.19,37 Long-term medicinal iron supplementation
was also associated with a reduced prevalence of iron
deficiency and/or iron deficiency anemia.17,24,33,41
Marginally LBW infants supplemented with 2mg/kg/d
had a lower prevalence of iron depletion, iron defi-
ciency, and anemia at both 6 and 12months than those
in the placebo group.17,24 Comparable findings were
reported in an initiation timing trial; 15% of infants
supplemented at 1week of age had iron deficiency
compared to 40% of those initiated at 8.5 weeks.33
Growth. Twelve papers investigated the effects of iron sup-
plementation on growth-related parameters – namely,
weight, length, and head circumference.17–21,24,25,30–32,35,36
In 6 short-term interventions, no effect of medicinal iron,
formula, or fortifier on any growth-related parameters
was observed.18,20,21,25,31,35 In the only short-term inter-
vention with long-term follow-up, high-dose (average
10.4mg/kg/d) iron had no effect on weight, length, or
head circumference up to 24months corrected age
(CA).20 Six articles reported that long-term supplemen-
tation had no effect on growth,17,19,24,30,32,36 including a
high-dose (7.1mg/kg/d) medicinal iron RCT in LBW
infants.36 Long-term supplementation of 1–2mg/kg/d
Table 3 Assessment of risk of bias in the studies reported on in the 27 articles included in the present review
Reference Random
sequence
generation
Allocation
concealment
Blinding of
participants/
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Berglund et al (2018)16 Low risk Low risk Low risk Low risk High risk Low risk
Berglund et al (2015)17 Low risk Low risk Low risk Low risk Low risk Low risk
Joy et al (2014)18 Low risk Low risk High risk Low risk Low risk Low risk
van de Lagemaat et al (2014)19 Low risk Low risk Low risk Low risk Low risk Low risk
Miller (2013)20 Low risk Low risk Low risk Low risk High risk Low risk
Taylor and Kennedy (2013)21 Low risk Low risk Low risk Low risk Low risk Low risk
Berglund et al (2013)22 Low risk Low risk Low risk Low risk Low risk Low risk
Berglund et al (2011)23 Low risk Low risk Low risk Low risk High risk Low risk
Berglund et al (2010)24 Low risk Low risk Low risk Low risk Low risk Low risk
Sankar et al. (2009)25 Low risk Low risk High risk Low risk Low risk Low risk
Steinmacher et al (2007)26 Low risk Unclear Low risk Low risk Low risk Low risk
Braekke et al (2007)27a High risk High risk High risk High risk Low risk Low risk
Arnon et al (2007)28 Low risk Unclear Low risk Low risk High risk Low risk
Miller et al (2006)29a High risk High risk High risk High risk Low risk Low risk
Aggarwal et al (2005)30 Low risk Unclear Low risk Low risk High risk Low risk
Berseth et al (2004)31 Low risk Unclear Low risk Low risk High risk Low risk
Friel et al (2001)32 Low risk Unclear Low risk Low risk High risk Low risk
Franz et al (2000)33 Low risk Unclear Low risk Low risk High risk Low risk
Griffin et al (1999)34 Low risk Unclear Low risk Low risk Low risk Low risk
Hall et al (1993)35 Low risk Unclear Low risk Low risk High risk Low risk
Barclay et al (1991)36 Unclear Unclear Unclear Unclear Low risk Low risk
Iwai et al (1986)37a High risk High risk High risk High risk Unclear Low risk
Halliday et al (1983)38 Low risk Unclear Low risk Unclear Unclear Low risk
Rudolph et al (1981)39 Low risk Unclear High risk High risk High risk Low risk
Jansson et al (1979)40 Low risk Unclear Unclear Unclear Low risk Low risk
Lundstrom et al (1977)41 High risk High risk Unclear Unclear Low risk Low risk
Brozovic et al (1974)42a High risk High risk High risk High risk Low risk Low risk
aNonrandomized trial – risk of selection bias also assessed in these studies.
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had no effect on long-term growth to 3.5 years of age in
marginally LBW infants.17,24
Neurological development. Seven articles reported on
studies that explored the effect of iron supplementation
on neurological development, as summarized in Table
4.16,18,20,22,23,26,32 Short-term supplementation had no
effect on neurological development in 2 RCTs,18,20 in-
cluding a high-dose (average 10.4mg/kg/d) trial with
outcomes assessed to 2 years of age.20 In an initiation
timing trial of 2–4mg/kg/d, while no effect on cogni-
tion, motor function, visual impairment, or behavior
was observed at 5 years CA, there was a trend towards
benefit of early initiation; 35% of the late initiation
group had an abnormal neurological examination result
compared to 19% of the early initiation group.26 While
no effect of long-term supplementation on
neurophysiological functioning – assessed using audi-
tory brainstem responses – was observed at 6months in
a Swedish RCT in marginally LBW infants,23 supple-
mented children had a significantly lower prevalence of
behavioral problems than those in the placebo group
(3% vs 13%, respectively) at 3.5 years22 and had signifi-
cantly lower scores in externalizing-type behaviors (ag-
gression/attention seeking) at 7 years.16
Adverse clinical outcomes. Nine articles reported the ef-
fect of supplementation on the incidence of short-term
adverse clinical outcomes, including necrotizing entero-
colitis, retinopathy of prematurity, chronic lung disease,
periventricular leukomalacia, oxidative stress, and sepsis
(Table 518,21,25,27–29,31,32,36). Short-term supplementation
with medicinal iron or human milk fortifier at 2–4mg/
kg/d had no effect in 4 RCTs.18,21,25,31 High-dose
Table 4 Effect of enteral iron supplementation on neurological development in preterm and low-birth-weight infants
Reference Duration of
intervention
Age at
follow-upa
Outcome assessment Main findings
Berglund et al
(2018)16
4.5mo 7 y Wechsler Scale of Intelligence No significant differences between
treatment groups in Wechsler Scale
or Five-to-Fifteen scores.
Child Behavior Checklist
Five-to-Fifteen questionnaire Children in placebo group had signifi-
cantly higher Child Behavior
Checklist scores for externalizing
problems than did supplemented
groups.
Joy et al (2014)18 6–10wk 12wk Hammer-Smith neurological
examination
No significant difference between
treatment groups in prevalence of
neurological deficits.
Miller et al
(2013)20
3 wk 6 and 24mo CA Bayley Scales of Infant
Development (3rd Edition)
No significant difference between treat-
ment groups in scores at 6 or 24mo
CA.
Berglund et al
(2013)22
4.5mo 3.5 y Wechsler Scale of Intelligence No significant difference between treat-
ment groups on Wechsler Scale.
Child Behavior Checklist Significantly higher prevalence of Child
Behavior Checklist total problem
scores > US subclinical cutoff in pla-
cebo group compared to supple-
mented groups.
Berglund et al
(2011)23
4.5mo 6mo Auditory brainstem responses No significant difference between treat-
ment groups in auditory brainstem
response wave V latencies.
Central conduction time significantly
higher in treatment group but not
correlated to iron intake.
Steinmacher et al
(2007)26
NR 5 y CA Gross Motor Functioning
Classification Scale
Significantly higher prevalence of ab-
normal results on standard neurolog-
ical examination in late group
compared to early group.
Lincoln-Oseretsky Scale No significant differences between
groups in any other developmental
measures.
Kaufman Assessment Battery
Visual impairment
Child Behavior Checklist
Friel et al (2001)32 1 y 3, 6, 9, 12mo CA Griffiths Mental Development
Assessment
No significant difference between treat-
ment groups in assessment scores at
any time point.
aChronological age, unless otherwise stated.
Abbreviation: CA, corrected age; NR, not reported.
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(5mg/kg/d) iron for <8weeks also had no effect on
adverse outcomes, including measures of oxidative
stress, in 1 timing RCT and 2 nonrandomized trials.27–29
Measures of antioxidant activity/oxidative stress
were reported in 2 long-term RCTs.32,36 Erythrocyte su-
peroxide dismutase activity decreased in the high-iron
(7.1mg/kg/d) group during a 16-week RCT, with no
changes observed in the low-iron (3.6mg/kg/d) or no-
iron groups, although no effect was seen with other
markers of copper metabolism or plasma zinc.36 In
1 year-long RCT, glutathione peroxidase activity was
slightly higher in the high-iron formula (3.4mg/kg/d)
group than in the normal (2.1mg/kg/d) formula group
at study-end, but no differences in superoxide dismutase
activity, malondialdehyde, or catalases were observed.32
DISCUSSION
This systematic review provides an important update
on the evidence regarding the effect of enteral iron sup-
plementation on health outcomes in preterm and LBW
infants. Since the 2010 recommendations for preterm
infants, an additional 8 papers have been published,
based on 5 trials. Despite this new evidence, questions
about the long-term health benefits or risks of enteral
iron supplementation in preterm and LBW infants,
over and above improved iron status, still remain.
Consistent with the evidence in term-born infants
and children,43,44 iron supplementation for 8weeks
appears to result in improved iron status in preterm
and LBW infants, with ferritin and hemoglobin the
most frequently reported indices. There is little to no
benefit of short-term supplementation (<8wk) in this
population. Worryingly, the long-term effect of supple-
mentation remains unclear; only 1 trial, published in
2015, measured iron indices beyond 1 year of age.17
Long-term supplementation was associated with a de-
creased prevalence of iron deficiency and anemia in
preterm and LBW infants, although, only 9 of the
articles in this review reported data on the prevalence of
iron deficiency. The reporting of prevalence data ena-
bles meaningful comparisons across studies; investigat-
ing a supplementation effect on individual indices in
isolation is of limited benefit in terms of understanding
the clinical condition itself. However, to achieve this,
the current uncertainty regarding the appropriate diag-
nostic criteria for iron deficiency in this population
should be addressed as a matter of urgency.
A U-shaped curve of risk is associated with iron, as
both deficiency and overload can lead to impaired
health outcomes.43,45 Excess iron has been associated
with decreased growth, impaired cognitive develop-
ment, and an increased risk of infection, with evidence
also emerging of altered gut microbiota in infants and
young children.45,46 Preterm infants are particularly
vulnerable to iron overload; however, the issue of over-
load was largely not addressed by the articles in this re-
view. Further consideration of overload and its
potential consequences in this vulnerable population is
warranted, especially in very preterm infants who often
receive multiple blood transfusions during their hospi-
tal stay.47 As hemoglobin concentrations alone do not
provide enough insight into the development of iron
overload, clinical management should also include the
routine measurement of ferritin concentrations, partic-
ularly during the inpatient period. This would facilitate
the establishment of more personalized and tailored
supplementation regimens; for example, in infants with
elevated ferritin concentrations (>300mg/L), supple-
mentation could be delayed or ceased temporarily until
their ferritin concentrations return to normal.9,48
Further investigation into the suitability of other iron
indices, such as transferrin receptors, in this population
is also necessary.
While excess free iron has been postulated to play a
role in the etiology of some neonatal diseases,49–51 this
Table 5 Effect of enteral iron supplementation on incidence of adverse short-term clinical outcomes in preterm and low-
birth-weight infants
Reference Necrotizing
enterocolitis
Retinopathy of
prematurity
Chronic
lung
disease
Periventricular
leukomalacia
Oxidative stress Sepsis
Joy et al (2014)18 No effect No effect Not reported No effect Not reported Not reported
Taylor and Kennedy
(2013)21
No effect Not reported No effect Not reported Not reported No effect
Sankar et al (2009)25 No effect No effect No effect No effect Not reported No effect
Braekke et al (2007)27 Not reported Not reported Not reported Not reported No effect Not reported
Arnon et al (2007)28 No effect No effect No effect No effect Not reported No effect
Miller et al (2006)29 Not reported Not reported Not reported Not reported No effect Not reported
Berseth et al (2004)31 No effect Not reported Not reported Not reported Not reported No effect
Friel et al (2001)32 Not reported Not reported Not reported Not reported Glutathione peroxidase higher
in high iron group
Not reported
Barclay et al (1991)36 Not reported Not reported Not reported Not reported Superoxide dismutase lower
in high iron group
Not reported
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review found no reported evidence of an increased risk
of necrotizing enterocolitis, retinopathy of prematurity,
chronic lung disease, periventricular leukomalacia, or
sepsis with supplementation. Two RCTs observed slight
changes in oxidative stress markers following long-term
supplementation, but the clinical significance of these
changes are unclear as long-term follow-up was not
implemented.32,36 No other studies of high-dose supple-
mentation reported adverse effects,
27–29
although it is im-
portant to note that the evidence to date is inadequate,
particularly given the wide variability in the monitoring
of adverse outcomes in trials, in both the frequency and
type of clinical data collected. Trials need to include the
systematic collection of adverse outcome data, thereby
enabling an accurate assessment of the potential risks of
supplementation, which is yet to be achieved.
Adverse effects of iron supplementation for growth
in iron-replete infants and young children have been
reported.45 In this review, there was no evidence that
short- or long-term iron supplementation had any ad-
verse or beneficial effects on growth in preterm and
LBW infants. There is still insufficient evidence regard-
ing the effect on long-term growth: only 2 trials assess-
ing growth-related parameters beyond the first year of
life were published in the intervening years since the
recommendations.17,20 Most studies included measure-
ments of weight, length, and head growth only, with ac-
tual or z-score changes in growth parameters reported
by relatively few of the included articles. Moreover, the
potential effect of iron supplementation on body com-
position in this population is yet to be investigated.
The evidence regarding the effect of iron supple-
mentation on neurological development in preterm and
LBW infants is limited. Only 7 articles reported on
studies that evaluated neurological development; while
5 of these articles were published since the 2010 recom-
mendations, 3 were based on the same trial in margin-
ally LBW infants. There was no evidence of an effect of
supplementation on cognition in preterm and LBW
infants; however, long-term supplementation was sug-
gested to have a positive effect on behavior, albeit only
in that trial of marginally LBW infants.16,22 The effect of
supplementation in the most vulnerable infants, partic-
ularly those born very preterm or with a birth weight
<1500 g, is yet to be elucidated. This paucity of data,
combined with the significant methodological differen-
ces in assessments, have made it difficult to draw mean-
ingful conclusions in this review. Further, the difficulty
in determining the effect of iron supplementation,
above and beyond the potential effect of other
comorbidities, is a significant challenge in this vulnera-
ble population.
The extensive search strategy and prospective pro-
tocol registration are strengths of this review, although
the search was limited to English language articles only.
The generalizability of this review’s findings is limited
to high-resource settings, where the studies were pre-
dominately conducted.
While limited evidence was available on which to
base the 2010 recommendations, this review has not
identified sufficient quantities of appropriate, consistent
evidence published since then to formulate revised rec-
ommendations from the perspectives of dosing or dura-
tion of supplementation. The substantial heterogeneity
in trial design with respect to participant characteristics,
intervention regimens, outcome assessments, and
follow-up has limited study comparisons. In particular,
the iron dose administered in trials conducted both pre
and post the 2010 recommendations has been variable,
making it difficult to truly assess the benefits or risks of
higher doses. The most effective delivery method for
iron in this population remains unclear, especially given
the lack of consideration given by many investigators to
the variability in iron concentration and bioavailability
of different feeding methods. The significant difference
in participants’ underlying medical care is another chal-
lenge that is often unaccounted for, particularly with re-
spect to placental transfusion methods, use of blood
transfusions, nutritional management, or other nutrient
supplementation.
CONCLUSION
Long-term iron supplementation appears to result in
improved iron status, coupled with a decrease in iron
deficiency and anemia in preterm and LBW infants. No
beneficial or adverse effects of supplementation on
short-term growth outcomes have been reported.
However, there remains a paucity of high-quality evi-
dence on the effect of iron supplementation on other
health outcomes, in particular with respect to long-term
growth and neurological development. The potential
adverse effects of supplementation, particularly the risk
of iron overload, require further consideration.
The 2010 recommendations for enteral iron sup-
plementation in preterm infants should continue to be
implemented. However, adjustments in clinical practice
should be carefully considered. Tailored supplementa-
tion regimens for individual patients, based on routine
monitoring of iron status indices, particularly
hemoglobin and ferritin, should be formulated for all
hospitalized preterm and LBW infants, particularly
those in receipt of multiple blood transfusions.
Advancement of this research field is necessary be-
fore the current recommendations can be updated.
However, the ethical constraints of conducting a
placebo-controlled trial in this vulnerable population
group present a significant challenge. Therefore, well-
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designed, long-term, dose-response RCTs, comparing 2
or more iron doses and including a fortified human
milk control group, are required to ascertain the opti-
mal dose and delivery method for the provision of iron
in preterm infants. Follow-up of short-, medium-, and
long-term health outcomes is essential, while further
consideration of the most vulnerable infants, particu-
larly those born very preterm, is also needed.
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